The development of human hematopoietic prostaglandin D2 synthase inhibitors in allergic asthma and related disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1039255

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Prostaglandin D2 (PGD2) is a key mediator of asthma and allergic rhinitis. We have developed drug-like compounds that block the synthesis of PGD2 by inhibiting the hematopoietic prostaglandin D2 synthase (HPGD2S) enzyme. This project aims to evaluate the potential of these compounds to treat asthma and to further optimize the drug-like characteristics of our lead molecules.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Development Grants

Funding Amount: $428,071.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

asthma | chronic obstructive pulmonary disease (COPD) | drug discovery | medicinal chemistry | respiratory diseases

Related Links